Cephalosporin Drugs Market, By Generation (First-generation, Cephalosporin, Second-generation Cephalosporin, Third-generation Cephalosporin, Fourth-generation Cephalosporin, and Fifth-generation Cephalosporin), By Type (Branded Cephalosporin Drugs and Generic Cephalosporin Drugs), By Formulation (Oral (Tablets, Capsules, and Liquid) and Injection), By Indication (Respiratory Tract Infection, Skin Infection, Ear Infection, Bacterial Infection, Urinary Tract Infection, Sexually Transmitted Infection, Sinus Infection, Surgical Prophylaxis, and Others (Meningitis, Acute Abdomen Infection, and Pelvic infection)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Trends, and Forecast 2019 - 2026

  • Published On : Jul 2019 |
  • Pages : 236 Pages |
  • Format : CMI Insight PPT Format CMI Insight PDF Format

Global Cephalosporin Drugs Market – Insights

Cephalosporin is a large group of antibiotics that belongs to a class known as beta-lactams. Cephalosporin is a wide spectrum bactericidal antibiotic used for the treatment of several bacterial infections. Cephalosporin drugs are available as both branded and generic medicines. Different generations of cephalosporin are used and preferred for different indications. The third-generation is the most prescribed and broad-spectrum antimicrobial agents useful in a variety of clinical situations. Cefotaxime and ceftizoxime have the best gram-positive bactericidal activity of the third-generation cephalosporin. Ceftazidime and cefoperazone are the only third-generation drugs that provide anti-pseudomonal coverage. Ceftriaxone's long half-life allows for once-daily dosing, making ceftriaxone an excellent drug for outpatient antibiotic therapy of community-acquired infections.

The global cephalosporin drugs market size was valued at US$ 14,240.0 million in 2018, and is expected to witness a CAGR of 3.8% over the forecast period (2019 – 2026).

Global Cephalosporin Drugs Market Share (%) Analysis, By Generation, 2018 & 2026    

Cephalosporin Drugs  | Coherent Market Insights

Source: Coherent Market Insights Analysis (2019)

Increasing Drug Approvals and R&D Activities is expected to Drive Growth of the Cephalosporin Drugs Market

Approvals and launch of novel products is expected to be a major factor driving the global cephalosporin drugs market growth over the forecast period. For instance, in June 2019, Merck & Co. announced that the U.S. Food and Drug Administration (FDA) approved its supplemental New Drug Application (sNDA) for the use of ZERBAXA (ceftolozane and tazobactam) for the treatment of patients 18 years and older with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.

Increasing research and development activities has spurred growth of the cephalosporin drugs market. For instance, in November 2017, B. Braun Medical Inc. initiated a clinical trial of Cefazolin infusion evaluating the safety of 1 g and 2 g of Cefazolin in pediatric subjects. The study is in phase 4 and is expected to be completed in July 2019. Therefore, increasing research on cephalosporin drugs is expected to create a favorable environment for the cephalosporin drugs market growth over the forecast period.

Global Cephalosporin Drugs Market - Restraints

Increasing cephalosporin drug recalls by regulatory bodies is hampering the cephalosporin drugs market growth. For instance, in August 2014, Caraco Pharmaceutical Laboratories Ltd., a unit of Sun Pharmaceutical Industries Ltd., initiated a recall of multiple lots of Cephalexin capsules from the U.S. market. According to a notification by the U.S. FDA, the recall of 340,553 units of 500 mg and 113,677 units of 250 mg bottles was voluntarily initiated by the company through a letter to the regulator in June 2014 under ‘Class-II’ classification, owing to Current Good Manufacturing Practice (CGMP) deviations.

Global Cephalosporin Drugs Market - Regional Insights

On the basis of region, the global cephalosporin drugs market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold a dominant position in the global cephalosporin drugs market during the forecast period, owing to increasing number of product launches. For instance, in August 2017, Dr. Reddy’s Laboratories Ltd. launched Cefixime for Oral Suspension, a therapeutic equivalent generic version of Suprax (cefixime) for Oral Suspension, in the U.S. market. The Suprax brand and generic had US sales of approximately US$ 50.5 million for the 12 months ended in June 2017.

Asia Pacific is expected to foresee a rapid growth in the cephalosporin drugs market. The market in Asia Pacific is expected to gain momentum during the forecast period, owing to increasing strategic partnership for distribution of cephalosporin drugs. For instance, in September 2017, Basilea Pharmaceutica Ltd. announced that its subsidiary, Basilea Pharmaceutica International Ltd. (Basilea), entered into a license agreement with Shenzhen China Resources Gosun Pharmaceutical Co., Ltd. for Basilea's antibiotic Zevtera (ceftobiprole) in China.

Global Cephalosporin Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2019-2026

   Cephalosporin Drugs  | Coherent Market Insights

 Source: Coherent Market Insights Analysis (2019)

Key players operating in the global cephalosporin drugs market include, Merck & Co. Inc., GlaxoSmithKline plc., Pfizer Inc., Allergan plc., Abbott Laboratories, Basilea Pharmaceutica Ltd., Sanofi S.A., F. Hoffmann-La Roche AG, Lupin Limited, Teva Pharmaceutical Industries Ltd., and B. Braun Melsungen AG.

Cephalosporin drugs are a group of broad-spectrum, semi-synthetic beta-lactam antibiotics generally used for the treatment of bacterial infections such as bacterial meningitis, otitis media, pneumonia, tuberculosis, upper respiratory tract infection, eye infections, sinusitis, urinary tract infections, skin infections, and sexually transmitted diseases. Most commonly used cephalosporin are cephalexin, ceftriaxone, cefixime, cefdinir, and cefaclor. The cephalosporin drugs market holds a huge potential in the sub-Saharan countries of Africa such as Ethiopia, Ghana, Nigeria, and Senegal, as these countries have high prevalence of bacterial infections due to underdeveloped healthcare facilities and infrastructure. For instance, according to the World Health Organization’s (WHO) report of February 2018, the highest burden of this disease is in the belt of sub-Saharan Africa, stretching from Senegal in the west to Ethiopia in the east. Around 30,000 cases are still reported each year from that area.

Market Dynamics

Increasing prevalence of respiratory tract infections worldwide is expected to boost the cephalosporin drugs market growth. For instance, according to the report of The Global Impact of Respiratory Disease in 2017, lower respiratory tract infection and pneumonia are two of the leading causes of death, accounting for over 4 million fatalities, annually. Furthermore, pneumonia killed 920,136 children aged under 5 years in 2015, accounting for 15% of the deaths in this age group. Streptococcus pneumoniae remains the most frequent bacterial cause of pneumonia, accounting for deaths of 393,000 children aged under 5 years in 2015.

However, factors such as increasing Food and Drug Administration (FDA) recalls is hindering the cephalosporin drugs market growth. For instance, in June 2019, Lupin Limited recalled 18,604 bottles (60 ml) of Cefdinir (Cephalosporin) for Oral Suspension, used for the treatment of bacterial infections, from the U.S. market. Furthermore, in January 2019, the company announced recall of 287,784 bottles of Cefdinir for Oral Suspension in the U.S. due to CGMP (Current Good Manufacturing Practice) deviations.

Key features of the study:

  • This report provides in-depth analysis of the cephalosporin drugs market, market size (US$ Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period: 2019 – 2026, considering 2018 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global cephalosporin drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include, Merck & Co. Inc., GlaxoSmithKline plc., Pfizer Inc., Allergan plc., Abbott Laboratories, Basilea Pharmaceutica Ltd., Sanofi S.A., F. Hoffmann-La Roche AG, Lupin Limited, Teva Pharmaceutical Industries Ltd., and B. Braun Melsungen AG
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
  • The global cephalosporin drugs market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for cephalosporin drugs market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

  • Global Cephalosporin Drugs Market, By Generation:
    • First-generation Cephalosporin
    • Second-generation Cephalosporin
    • Third-generation Cephalosporin
    • Fourth-generation Cephalosporin
    • Fifth-generation Cephalosporin
  • Global Cephalosporin Drugs Market, By Type:
    • Branded Cephalosporin Drugs
    • Generic Cephalosporin Drugs
  • Global Cephalosporin Drugs Market, By Formulation:
    • Oral
      • Tablets
      • Capsules
      • Liquid
    • Injection
  • Global Cephalosporin Drugs Market, By Indication:
    • Respiratory Tract Infection
    • Skin Infection
    • Ear Infection
    • Bacterial Infection
    • Urinary Tract Infection
    • Sexually Transmitted Infection
    • Sinus Infection
    • Surgical Prophylaxis
    • Others (Meningitis, Acute Abdomen Infection, and Pelvic Infection)
  • Global Cephalosporin Drugs Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Cephalosporin Drugs Market, By Region:
    • North America
      • By Country:
        • U.S.
        • Canada
      • By Generation:
        • First-generation Cephalosporin
        • Second-generation Cephalosporin
        • Third-generation Cephalosporin
        • Fourth-generation Cephalosporin
        • Fifth-generation Cephalosporin
      • By Type:
        • Branded Cephalosporin Drugs
        • Generic Cephalosporin Drugs
      • By Formulation:
        • Oral
          • Tablets
          • Capsules
          • Liquid
        • Injection
      • By Indication:
        • Respiratory Tract Infection
        • Skin Infection
        • Ear Infection
        • Bacterial Infection
        • Urinary Tract Infection
        • Sexually Transmitted Infection
        • Sinus Infection
        • Surgical Prophylaxis
        • Others (Meningitis, Acute Abdomen Infection, and Pelvic Infection)
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Europe
      • By Country:
        • U.K.
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • Rest of Europe
      • By Generation:
        • First-generation Cephalosporin
        • Second-generation Cephalosporin
        • Third-generation Cephalosporin
        • Fourth-generation Cephalosporin
        • Fifth-generation Cephalosporin
      • By Type:
        • Branded Cephalosporin Drugs
        • Generic Cephalosporin Drugs
      • By Formulation:
        • Oral
          • Tablets
          • Capsules
          • Liquid
        • Injection
      • By Indication:
        • Respiratory Tract Infection
        • Skin Infection
        • Ear Infection
        • Bacterial Infection
        • Urinary Tract Infection
        • Sexually Transmitted Infection
        • Sinus Infection
        • Surgical Prophylaxis
        • Others (Meningitis, Acute Abdomen Infection, and Pelvic Infection)
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Asia Pacific
      • By Country:
        • Australia
        • India
        • China
        • Japan
        • ASEAN
        • South Korea
        • Rest of Asia Pacific
      • By Generation:
        • First-generation Cephalosporin
        • Second-generation Cephalosporin
        • Third-generation Cephalosporin
        • Fourth-generation Cephalosporin
        • Fifth-generation Cephalosporin
      • By Type:
        • Branded Cephalosporin Drugs
        • Generic Cephalosporin Drugs
      • By Formulation:
        • Oral
          • Tablets
          • Capsules
          • Liquid
        • Injection
      • By Indication:
        • Respiratory Tract Infection
        • Skin Infection
        • Ear Infection
        • Bacterial Infection
        • Urinary Tract Infection
        • Sexually Transmitted Infection
        • Sinus Infection
        • Surgical Prophylaxis
        • Others (Meningitis, Acute Abdomen Infection, and Pelvic Infection)
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Latin America
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
      • By Generation:
        • First-generation Cephalosporin
        • Second-generation Cephalosporin
        • Third-generation Cephalosporin
        • Fourth-generation Cephalosporin
        • Fifth-generation Cephalosporin
      • By Type:
        • Branded Cephalosporin Drugs
        • Generic Cephalosporin Drugs
      • By Formulation:
        • Oral
          • Tablets
          • Capsules
          • Liquid
        • Injection
      • By Indication:
        • Respiratory Tract Infection
        • Skin Infection
        • Ear Infection
        • Bacterial Infection
        • Urinary Tract Infection
        • Sexually Transmitted Infection
        • Sinus Infection
        • Surgical Prophylaxis
        • Others (Meningitis, Acute Abdomen Infection, and Pelvic Infection)
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Middle East
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
      • By Generation:
        • First-generation Cephalosporin
        • Second-generation Cephalosporin
        • Third-generation Cephalosporin
        • Fourth-generation Cephalosporin
        • Fifth-generation Cephalosporin
      • By Type:
        • Branded Cephalosporin Drugs
        • Generic Cephalosporin Drugs
      • By Formulation:
        • Oral
          • Tablets
          • Capsules
          • Liquid
        • Injection
      • By Indication:
        • Respiratory Tract Infection
        • Skin Infection
        • Ear Infection
        • Bacterial Infection
        • Urinary Tract Infection
        • Sexually Transmitted Infection
        • Sinus Infection
        • Surgical Prophylaxis
        • Others (Meningitis, Acute Abdomen Infection, and Pelvic Infection)
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Africa
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
      • By Generation:
        • First-generation Cephalosporin
        • Second-generation Cephalosporin
        • Third-generation Cephalosporin
        • Fourth-generation Cephalosporin
        • Fifth-generation Cephalosporin
      • By Type:
        • Branded Cephalosporin Drugs
        • Generic Cephalosporin Drugs
      • By Formulation:
        • Oral
          • Tablets
          • Capsules
          • Liquid
        • Injection
      • By Indication:
        • Respiratory Tract Infection
        • Skin Infection
        • Ear Infection
        • Bacterial Infection
        • Urinary Tract Infection
        • Sexually Transmitted Infection
        • Sinus Infection
        • Surgical Prophylaxis
        • Others (Meningitis, Acute Abdomen Infection, and Pelvic Infection)
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
  • Company Profiles
    • Merck & Co. Inc.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
  • GlaxoSmithKline plc.
  • Pfizer Inc.
  • Allergan plc.
  • Abbott Laboratories
  • Basilea Pharmaceutica Ltd.
  • Sanofi S.A.
  • Hoffmann-La Roche AG
  • Lupin Limited
  • Teva Pharmaceutical Industries Ltd.
  • Braun Melsungen AG

 “*” marked represents similar segmentation in other categories in the respective section

Table of Contents

  1. Research Objective and Assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Overview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Generation
      • Market Snippet, By Type
      • Market Snippet, By Formulation
      • Market Snippet, By Indication
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Market Trends
    • Key Developments
    • Major Brand Analysis
    • Reimbursement Scenario
    • Epidemiology Analysis
    • Porter’s Five Forces Model
    • Pipeline Analysis
    • Switch Analysis
    • Site Chain Analysis
  4. Global Cephalosporin Drugs Market
    • Antibiotic Resistance Trends By Country
  5. Global Cephalosporin Drugs Market, By Generation, 2019 – 2026, (US$ Million)
    • Introduction
      • Market Share Analysis, 2019 and 2026 (%)
      • Y-o-Y Growth Analysis, 2018 – 2026
      • Segment Trends
    • First-generation Cephalosporin
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2026, (US$ Million)
    • Second-generation Cephalosporin
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2026, (US$ Million)
    • Third-generation Cephalosporin
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2026, (US$ Million)
    • Fourth-generation Cephalosporin
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2026, (US$ Million)
    • Fifth-generation Cephalosporin
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2026, (US$ Million)
  6. Global Cephalosporin Drugs Market, By Type, 2019 – 2026, (US$ Million)
    • Introduction
      • Market Share Analysis, 2019 and 2026 (%)
      • Y-o-Y Growth Analysis, 2018 – 2026
      • Segment Trends
    • Branded Cephalosporin Drugs
      • Market Share Analysis, 2019 and 2026 (%)
      • Y-o-Y Growth Analysis, 2018 – 2026
      • Segment Trends
    • Generic Cephalosporin Drugs
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2026, (US$ Million)
  7. Global Cephalosporin Drugs Market, By Formulation, 2019 – 2026, (US$ Million)
    • Introduction
      • Market Share Analysis, 2019 and 2026 (%)
      • Y-o-Y Growth Analysis, 2018 – 2026
      • Segment Trends
    • Oral
      • Market Share Analysis, 2019 and 2026 (%)
      • Y-o-Y Growth Analysis, 2018 – 2026
      • Segment Trends
        • Tablets
        • Capsules
        • Liquid
    • Injection
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2026, (US$ Million)
  8. Global Cephalosporin Drugs Market, By Indication, 2019 – 2026, (US$ Million)
    • Introduction
      • Market Share Analysis, 2019 and 2026 (%)
      • Y-o-Y Growth Analysis, 2018 – 2026
      • Segment Trends
    • Respiratory Tract Infection
      • Market Share Analysis, 2019 and 2026 (%)
      • Y-o-Y Growth Analysis, 2018 – 2026
      • Segment Trends
    • Skin Infection
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2026, (US$ Million)
    • Ear Infection
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2026, (US$ Million)
    • Bacterial Infection
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2026, (US$ Million)
    • Urinary Tract Infection
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2026, (US$ Million)
    • Sexually Transmitted Infection
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2026, (US$ Million)
    • Sinus Infection
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2026, (US$ Million)
    • Surgical Prophylaxis
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2026, (US$ Million)
    • Others (Meningitis, Acute Abdomen Infection, and Pelvic Infection)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2026, (US$ Million)
  9. Global Cephalosporin Drugs Market, By Distribution Channel, 2019 – 2026, (US$ Million)
    • Introduction
      • Market Share Analysis, 2019 and 2026 (%)
      • Y-o-Y Growth Analysis, 2018 – 2026
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2026, (US$ Million)
    • Retail Pharmacies
      • Introduction  
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2026, (US$ Million)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2026, (US$ Million)
  10. Global Cephalosporin Drugs Market, By Region, 2019 – 2026, (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2019 and 2026 (%)
      • Y-o-Y Growth Analysis, By Region, 2018 – 2026
      • Regional Trends
    • North America
      • Market Size and Forecast, By Generation, 2019 – 2026, (US$ Million)
      • Market Size and Forecast, By Type, 2019 – 2026, (US$ Million)
      • Market Size and Forecast, By Formulation, 2019 – 2026, (US$ Million)
      • Market Size and Forecast, By Indication, 2019 – 2026, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2019 – 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2019 – 2026, (US$ Million)
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast, By Generation, 2019 – 2026, (US$ Million)
      • Market Size and Forecast, By Type, 2019 – 2026, (US$ Million)
      • Market Size and Forecast, By Formulation, 2019 – 2026, (US$ Million)
      • Market Size and Forecast, By Indication, 2019 – 2026, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2019 – 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2019 – 2026, (US$ Million)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Generation, 2019 – 2026, (US$ Million)
      • Market Size and Forecast, By Type, 2019 – 2026, (US$ Million)
      • Market Size and Forecast, By Formulation, 2019 – 2026, (US$ Million)
      • Market Size and Forecast, By Indication, 2019 – 2026, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2019 – 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2019 – 2026, (US$ Million)
        • China
        • Japan
        • India
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast, By Generation, 2019 – 2026, (US$ Million)
      • Market Size and Forecast, By Type, 2019 – 2026, (US$ Million)
      • Market Size and Forecast, By Formulation, 2019 – 2026, (US$ Million)
      • Market Size and Forecast, By Indication, 2019 – 2026, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2019 – 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2019 – 2026, (US$ Million)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Africa
      • Market Size and Forecast, By Generation, 2019 – 2026, (US$ Million)
      • Market Size and Forecast, By Type, 2019 – 2026, (US$ Million)
      • Market Size and Forecast, By Formulation, 2019 – 2026, (US$ Million)
      • Market Size and Forecast, By Indication, 2019 – 2026, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2019 – 2026, (US$ Million)
      • Market Size and Forecast, By Country/Region, 2019 – 2026, (US$ Million)
        • North Africa
        • Central Africa
        • South Africa
    • Middle East
      • Market Size and Forecast, By Generation, 2019 – 2026, (US$ Million)
      • Market Size and Forecast, By Type, 2019 – 2026, (US$ Million)
      • Market Size and Forecast, By Formulation, 2019 – 2026, (US$ Million)
      • Market Size and Forecast, By Indication, 2019 – 2026, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2019 – 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2019 – 2026, (US$ Million)
        • GCC Countries
        • Israel
        • Rest of Middle East
  11. Competitive Landscape
    • Company Profiles
      • Merck & Co. Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • GlaxoSmithKline plc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Pfizer Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Allergan plc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Abbott Laboratories
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Basilea Pharmaceutica Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Sanofi S.A.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • F. Hoffmann-La Roche AG
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Lupin Limited
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Teva Pharmaceutical Industries Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • B. Braun Melsungen AG
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
    • Analyst Views
  12. Section
    • References
    • Research Methodology
    • About Us and Sales Contact

*Browse 53 market data tables and 50 figures on "Cephalosporin Drugs Market” - Global forecast to 2026”

Research Methodology

Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:

  • Primary Research (Trade Surveys and Experts Interviews)
  • Desk Research
  • Proprietor Data Analytics Model

In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings.


Smiley face

Coherent Market Insights desk research is based on a principle set of research techniques:

  • National level desk research: It Includes research analysis of regional players, regional regulatory bodies, regional trade associations, and regional organization.
  • Multinational level desk research: The research team keeps a track of multinational players, global regulatory bodies, global trade associations, and global organization.

Coherent Market Insights has a large amount of in-house repository of industry database. This is leveraged as a burner for initiating a new research study. Key secondary sources include:

  • Governmental bodies, National and international social welfare institutions, and organizations creating economic policies among others.
  • Trade association, National and international media and trade press.
  • Company Annual reports, SEC filings, Corporate Presentations, press release, news, and specification sheet of manufacturers, system integrators, brick and mortar - distributors and retailers, and third party online commerce players.
  • Scientific journals, and other technical magazines and whitepapers.

Smiley face

Preliminary Data Mining

The raw data is obtained through the secondary findings, in house repositories, and trade surveys. It is then filtered to ensure that the relevant information including industry dynamics, trends, and outlook is retained for further research process.

Data Standardization:

Holistic approach is used to ensure that the granular and uncommon parameters are taken into consideration to ensure accurate results. The information from the paid databases are further combined to the raw data in order to standardize it.

Coherent Statistical model

We arrive at our final research findings through simulation models. Coherent Data Analytics Model is a statistical tool that helps company to forecast market estimates. Few of the parameters considered as a part of the statistical model include:

  • Micro-economic indicators
  • Macro-economic indicators
  • Environmental indicators
  • Socio-political indicators
  • Technology indicators

Data Processing

Once the findings are derived from the statistical model, large volume of data is process to confirm accurate research results. Data analytics and processing tools are adopted to process large chunk of collected informative data. In case, a client customizes the study during the process, the research finding till then are benchmarked, and the process for new research requirement is initiated again.

Data Validation

This is the most crucial stage of the research process. Primary Interviews are conducted to validate the data and analysis. This helps in achieving the following purposes:

  • It provides first-hand information on the market dynamics, outlook, and growth parameters.
  • Industry experts validates the estimates which helps the company to cement the on-going research study.
  • Primary research includes online surveys, face-to face interviews, and telephonic interviews.

The primary research is conducted with the ecosystem players including, but not limited to:

  • Raw Material Suppliers
  • Manufacturers
  • System Integrators
  • Distributors
  • End-users

Choose License Type

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

[email protected]

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.